Oxford Biomedica forms expert advisory board to drive innovation

LONDON - Oxford Biomedica PLC (LSE:OXB), a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has announced the formation of its Innovation and Technology Excellence Board (ITEB). The board, comprising distinguished experts in the fields of cell and gene therapy, scientific innovation, and advanced manufacturing, is set to provide strategic guidance to enhance OXB’s technological capabilities and support its growth trajectory.

The ITEB, which convened for the first time last month, aims to identify and capitalize on innovation opportunities, keeping OXB at the forefront of the rapidly progressing cell and gene therapy sector. This move is part of the company’s commitment to maintaining its market-leading position by offering cutting-edge solutions to its clients.

Dr. Frank Mathias, CEO of OXB, emphasized the importance of the advisory board in ensuring the company’s continued leadership in innovation and its ability to respond to scientific and technological advancements. By leveraging the collective expertise of the board members, OXB intends to refine its operational processes and aid clients in bringing transformative therapies to market.

Professor Dame Kay Davies, Chair of the ITEB and a renowned figure in human genetics, highlighted the board’s role in directing OXB’s innovation efforts towards practical advances in treatment development, manufacturing, and delivery. The overarching goal, according to Prof. Davies, is to translate innovation into tangible benefits for clients and improved patient outcomes.

The ITEB’s founding members are prominent figures in their respective fields, including Prof. Uwe Buecheler, Prof. Bruce Levine, Prof. Axel Schambach, and Prof. Luk Vandenberghe, who bring a wealth of experience and accomplishments in biopharmaceuticals, gene therapy, and related disciplines. Dr. Heather Preston, an Observer and Independent (LON:IOG) Non-Executive Director at OXB, also brings extensive healthcare and biotech investment experience to the board.

Senior OXB executives, including Dr. Frank Mathias, Thierry Cournez, Dr. Kyriacos Mitrophanous, and Dr. Sébastien Ribault, are also part of the ITEB, ensuring alignment between the board’s advisory role and the company’s operational leadership.

This initiative demonstrates OXB’s strategic approach to fostering innovation within its operations, aiming to solidify its position as a pure-play CDMO leader in the cell and gene therapy industry. The formation of the ITEB is based on a press release statement issued by the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.